Identification of a recurrent STRN/ALK fusion in thyroid carcinomas

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Pérot, Gaëlle ^a   Soubeyran, Isabelle ^a   Ribeiro, Agnès ^a   Bonhomme, Benjamin ^a   Savagner, Frédérique ^b   Boutet Bouzamondo, Nathalie ^b   Hostein, Isabelle ^a   Bonichon, Françoise ^a   Godbert, Yann ^a   Chibon, Frédéric ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CALMODULIN BINDING PROTEIN;

ALK GENE; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE CONTROL; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STRN GENE; THYROID CARCINOMA;

BASE SEQUENCE; CALMODULIN-BINDING PROTEINS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS;

EID: 84900341053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087170     Document Type: Article

References (27)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press pp. 51-80.
2. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184-199.
3. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
4. Sherman SI (2003) Thyroid carcinoma. Lancet 361:501-511.
5. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004;100:1123-9. (Pubitemid 38325938)
6. Baudin E, Schlumberger M (2007) New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8:148-156. (Pubitemid 46158381)
7. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, et al. (2006) Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899. (Pubitemid 44271732)
8. Schlumberger M, Sherman S (2012) Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166:5-11.
9. Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, et al. (2013) Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 31, No 18-suppl: 4.
10. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330-1335. (Pubitemid 40410726)
11. Smallridge RC (2012) Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 97:2566-2572.
12. Godbert Y, Henriques de Figueiredo B, Bonichon F, Chibon F, Hostein I, et al. Remarkable response to crizotinib in 71-year old woman with ALk-rearranged anaplastic thyroid carcinoma. J Clin Oncol. In press.
13. Pérot G, Croce S, Ribeiro A, Lagarde P, Velasco V, et al. (2012) MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 7:e40015.
14. Terrier-Lacombe MJ, Guillou L, Chibon F, Gallagher G, Benhattar J, et al. (2009) Superficial primitive Ewing's sarcoma: a clinicopathologic and molecular cytogenetic analysis of 14 cases. Mod Pathol 22:87-94.
15. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253.
16. Hamatani K, Mukai M, Takahashi K, Hayashi Y, Nakachi K, et al. (2012) Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. Thyroid 22:1153-1159.
17. Boonyaratanakornkit V (2011) Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor. Steroids 76:877-884.
18. Mano H (2012) ALKoma: a cancer subtype with a shared target. Cancer Discov 2:495-502.
19. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284. (Pubitemid 24107549)
20. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, et al. (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567-1574. (Pubitemid 24163381)
21. Bischof D, Pulford K, Mason DY, Morris SW (1997) Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17:2312-2325. (Pubitemid 27133318)
22. Rodrigues GA, Park M (1994) Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev 4:15-24. (Pubitemid 24060291)
23. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, et al. (2007) Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 138:77-81. (Pubitemid 46889792)
24. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, et al. (2013) Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 230:270-276.
25. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571.
26. Li Y, Pan Y, Wang R, Sun Y, Hu H, et al. (2013) ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR. PLoS One 8:e69016.
27. Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, et al. (2013) Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 8:e52261.